"Anticholesteremic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances used to lower plasma CHOLESTEROL levels.
| Descriptor ID |
D000924
|
| MeSH Number(s) |
D27.505.519.186.071.202 D27.505.954.557.500.202
|
| Concept/Terms |
Anticholesteremic Agents- Anticholesteremic Agents
- Agents, Anticholesteremic
- Inhibitors, Cholesterol
- Cholesterol Inhibitors
- Anticholesteremic Drugs
- Drugs, Anticholesteremic
- Anticholesteremics
|
Below are MeSH descriptors whose meaning is more general than "Anticholesteremic Agents".
Below are MeSH descriptors whose meaning is more specific than "Anticholesteremic Agents".
This graph shows the total number of publications written about "Anticholesteremic Agents" by people in this website by year, and whether "Anticholesteremic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 0 | 1 | 1 |
| 1996 | 4 | 2 | 6 |
| 1998 | 2 | 1 | 3 |
| 1999 | 2 | 1 | 3 |
| 2000 | 3 | 2 | 5 |
| 2001 | 5 | 2 | 7 |
| 2002 | 2 | 3 | 5 |
| 2003 | 6 | 3 | 9 |
| 2004 | 7 | 2 | 9 |
| 2005 | 6 | 2 | 8 |
| 2006 | 5 | 2 | 7 |
| 2007 | 5 | 1 | 6 |
| 2008 | 7 | 3 | 10 |
| 2009 | 5 | 1 | 6 |
| 2010 | 0 | 1 | 1 |
| 2011 | 4 | 4 | 8 |
| 2012 | 2 | 4 | 6 |
| 2013 | 1 | 2 | 3 |
| 2014 | 4 | 0 | 4 |
| 2015 | 5 | 2 | 7 |
| 2016 | 10 | 5 | 15 |
| 2017 | 7 | 3 | 10 |
| 2018 | 5 | 5 | 10 |
| 2019 | 6 | 4 | 10 |
| 2020 | 0 | 2 | 2 |
| 2021 | 4 | 1 | 5 |
| 2022 | 10 | 0 | 10 |
| 2023 | 12 | 0 | 12 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anticholesteremic Agents" by people in Profiles.
-
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
-
Oral PCSK9 Inhibitors. Curr Atheroscler Rep. 2024 05; 26(5):147-152.
-
LDL-C Lowering in Prevention of Atherosclerotic Cardiovascular Disease: Another Step Forward in This Lifelong Marathon. J Am Coll Cardiol. 2024 02 13; 83(6):665-668.
-
Inclisiran: Where Are We on Safety, Efficacy, and Clinical Effectiveness of?siRNA Therapies for Prevention? J Am Coll Cardiol. 2023 12 12; 82(24):2262-2264.
-
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress. Curr Atheroscler Rep. 2023 12; 25(12):965-978.
-
The 2022 American College of Cardiology Expert Consensus on the Role of Nonstatin Therapies: An Expert-Guided Tour. Tex Heart Inst J. 2023 11 17; 50(6).
-
The underutilization of preventive cardiovascular measures in patients with cancer: an analysis of the Behavioural Risk Factor Surveillance System, 2011-22. Eur J Prev Cardiol. 2023 09 20; 30(13):1325-1332.
-
Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials. Atherosclerosis. 2023 08; 378:117182.
-
Novel therapies to achieve the recommended low-density lipoprotein cholesterol concentration (LDL-C) targets for patients after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2024 02; 167(2):723-730.e4.
-
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023 Jul-Aug; 17(4):491-503.